130 related articles for article (PubMed ID: 13678212)
1. Self-assembled multivalent vancomycin on cell surfaces against vancomycin-resistant enterococci (VRE).
Xing B; Ho PL; Yu CW; Chow KH; Gu H; Xu B
Chem Commun (Camb); 2003 Sep; (17):2224-5. PubMed ID: 13678212
[TBL] [Abstract][Full Text] [Related]
2. Multivalent antibiotics via metal complexes: potent divalent vancomycins against vancomycin-resistant enterococci.
Xing B; Yu CW; Ho PL; Chow KH; Cheung T; Gu H; Cai Z; Xu B
J Med Chem; 2003 Nov; 46(23):4904-9. PubMed ID: 14584941
[TBL] [Abstract][Full Text] [Related]
3. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B.
Yoshida O; Yasukata T; Sumino Y; Munekage T; Narukawa Y; Nishitani Y
Bioorg Med Chem Lett; 2002 Nov; 12(21):3027-31. PubMed ID: 12372494
[TBL] [Abstract][Full Text] [Related]
4. Importance of the structure of vancomycin binding pocket in designing compounds active against vancomycin-resistant enterococci (VRE).
Jia Y; Bois-Choussy M; Malabarba A; Brunati C; Zhu J
J Antibiot (Tokyo); 2006 Sep; 59(9):543-52. PubMed ID: 17136887
[TBL] [Abstract][Full Text] [Related]
5. Reengineering Antibiotics to Combat Bacterial Resistance: Click Chemistry [1,2,3]-Triazole Vancomycin Dimers with Potent Activity against MRSA and VRE.
Silverman SM; Moses JE; Sharpless KB
Chemistry; 2017 Jan; 23(1):79-83. PubMed ID: 27747932
[TBL] [Abstract][Full Text] [Related]
6. The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci.
Arnusch CJ; Bonvin AM; Verel AM; Jansen WT; Liskamp RM; de Kruijff B; Pieters RJ; Breukink E
Biochemistry; 2008 Dec; 47(48):12661-3. PubMed ID: 18989934
[TBL] [Abstract][Full Text] [Related]
7. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.
Rodriguez MJ; Snyder NJ; Zweifel MJ; Wilkie SC; Stack DR; Cooper RD; Nicas TI; Mullen DL; Butler TF; Thompson RC
J Antibiot (Tokyo); 1998 Jun; 51(6):560-9. PubMed ID: 9711219
[TBL] [Abstract][Full Text] [Related]
8. Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.
Yoganathan S; Miller SJ
J Med Chem; 2015 Mar; 58(5):2367-77. PubMed ID: 25671771
[TBL] [Abstract][Full Text] [Related]
9. Genotypic Characterization of Vancomycin-Resistant Enterococcus spp. In Tertiary Center, Iran.
Shokouhi S; Darazam IA; Javadi A; Rouhani M; Ghasemnejad M
Infect Disord Drug Targets; 2017; 17(2):90-94. PubMed ID: 28228089
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal activities of disinfectants against vancomycin-resistant enterococci.
Sakagami Y; Kajimura K
J Hosp Infect; 2002 Feb; 50(2):140-4. PubMed ID: 11846542
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial activity of phytochemicals isolated from Erythrina zeyheri against vancomycin-resistant enterococci and their combinations with vancomycin.
Sato M; Tanaka H; Oh-Uchi T; Fukai T; Etoh H; Yamaguchi R
Phytother Res; 2004 Nov; 18(11):906-10. PubMed ID: 15597305
[TBL] [Abstract][Full Text] [Related]
12. Selective medium for screening for vancomycin-resistant enterococci in faeces.
Rao GG; Ghanekar K; Ojo F
Eur J Clin Microbiol Infect Dis; 1996 Feb; 15(2):175-7. PubMed ID: 8801094
[TBL] [Abstract][Full Text] [Related]
13. An efficient and practical method for solid-phase synthesis of tripeptide-bearing glycopeptide antibiotics: combinatorial parallel synthesis of carboxamide derivatives of chloroorienticin B.
Yasukata T; Shindo H; Yoshida O; Sumino Y; Munekage T; Narukawa Y; Nishitani Y
Bioorg Med Chem Lett; 2002 Nov; 12(21):3033-6. PubMed ID: 12372495
[TBL] [Abstract][Full Text] [Related]
14. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.
Franchi D; Climo MW; Wong AH; Edmond MB; Wenzel RP
Clin Infect Dis; 1999 Dec; 29(6):1566-8. PubMed ID: 10585815
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin-resistant enterococci.
Rubinstein E; Keynan Y
Crit Care Clin; 2013 Oct; 29(4):841-52. PubMed ID: 24094380
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of calozeyloxanthone isolated from Calophyllum species against vancomycin-resistant Enterococci (VRE) and synergism with antibiotics.
Sakagami Y; Kajimura K; Wijesinghe WM; Dharmaratne HR
Planta Med; 2002 Jun; 68(6):541-3. PubMed ID: 12094300
[TBL] [Abstract][Full Text] [Related]
17. Nitrofurantoin is active against vancomycin-resistant enterococci.
Zhanel GG; Hoban DJ; Karlowsky JA
Antimicrob Agents Chemother; 2001 Jan; 45(1):324-6. PubMed ID: 11120989
[TBL] [Abstract][Full Text] [Related]
18. Comparison of vancomycin-resistant enterococci isolates from human, poultry and pigs in Korea.
Seo KS; Lim JY; Yoo HS; Bae WK; Park YH
Vet Microbiol; 2005 Apr; 106(3-4):225-33. PubMed ID: 15778028
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS).
Zhanel GG; Laing NM; Nichol KA; Palatnick LP; Noreddin A; Hisanaga T; Johnson JL; Hoban DJ;
J Antimicrob Chemother; 2003 Sep; 52(3):382-8. PubMed ID: 12888592
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of vancomycin-resistant enterococci in Europe.
Schouten MA; Hoogkamp-Korstanje JA; Meis JF; Voss A;
Eur J Clin Microbiol Infect Dis; 2000 Nov; 19(11):816-22. PubMed ID: 11152305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
